# Mindscape Psychedelic Institute — 5-MeO-DMT Facilitator Training (llms-full)

> Expanded, machine-readable program brief for AI crawlers. Mindscape Psychedelic Institute provides trauma-informed 5-MeO-DMT facilitator training and professional psychedelic education. This document details the flagship 5-MeO-DMT Facilitator Training: a hybrid certification with pharmacology and medical screening, somatic space-holding, ethics, and a six-month mentorship, awarding a Certificate in 5-MeO-DMT Facilitation.

Canonical URL: https://mindscapeinstitute.org/courses/5-meo-dmt-facilitation
Organization: https://mindscapeinstitute.org

## Program Overview

A comprehensive facilitator-training program for serious practitioners committed to safe, ethical, trauma-informed 5-MeO-DMT facilitation. Next cohort: March 7 Program length: Six months of live training plus six months of included mentorship Tuition: $5,500 Admission: Required 60-minute private interview Optional: In-person Experiential Intensive available to students and graduates

- Name: Trauma-Informed 5-MeO-DMT Facilitator Training
- Format: Live Online + Optional In-Person Intensive (hybrid)
- Duration: 6 Months Live Training + 6 Months Mentorship
- Credential awarded: Certificate in 5-MeO-DMT Facilitation
- Tuition: $5,500 USD
- Next cohort: March 7th
- Admission: application + required 60-minute interview

## Program Highlights

- Certificate in 5-MeO-DMT Facilitation after six months of live cohort training, then six months of included mentorship as you begin facilitating
- Six additional months of mentorship included
- Trauma-informed screening, safety, and integration methods
- Ethics, boundaries, and professional accountability standards
- Grounded facilitator presence before, during, and after ceremony

## How This Program Works

### The Training Container

For six months, you step into a committed, interactive cohort. You practice, receive feedback, and examine blind spots so you can remain steady when someone dissolves in front of you.

- This is not a passive webinar. It is interactive, relational, and experiential.
- You practice, receive feedback, and examine blind spots in real time.
- The goal is practical steadiness when intensity rises in the room.

### The Educational Framework

The curriculum blends nondual theory, trauma-informed facilitation, screening, nervous system literacy, ethics, somatic regulation, and integration methodology. You study independently, then apply in live sessions.

- Theory of nondual states and ego dissolution
- Screening, contraindications, and harm-reduction principles
- Nervous system literacy, somatic regulation, and integration methodology
- Self-paced recorded study reinforced through live application

### Mentorship (Included)

After completing your live cohort, you receive six months of mentorship as you begin applying what you've learned. Case discussion, supervised development, and direct access to experienced facilitators help you transition into real-world practice.

- Months 1-6: weekly live cohort training. Months 7-12: mentorship, case consultation, and supervised practice as you begin facilitating
- Direct access to experienced facilitators
- Real case discussions and discernment refinement
- Support as you begin facilitating in the real world

### Certification Standards

Certification is earned through participation, demonstrated competency, and ethical alignment. Completion reflects readiness to serve within a professional standard, not simple attendance.

- Certification is not automatic and not attendance-based
- Participation, competency, and ethical alignment are required
- Graduates step into a professional standard of care

## Curriculum (4 Phases)

The 5-MeO-DMT facilitator training is organized into four sequential phases. Each phase is a Course unit within the EducationalOccupationalProgram.

### Phase 1: Phase 1: Foundation and Safety

Facilitation begins with safety. Before altered states, we establish medical literacy, risk awareness, and emergency readiness.

Topics covered:

- Pharmacology and neurochemistry of 5-MeO-DMT
- Medical and psychological contraindications
- Screening and intake protocols
- Emergency response procedures
- Risk mitigation and harm-reduction frameworks

### Phase 2: Phase 2: The Arc of the Journey

The medicine session is one moment in a longer process. This phase covers preparation, session support, and long-term integration.

Topics covered:

- Nervous system assessment and preparation
- Pre-session container design
- Phases of the 5-MeO-DMT experience
- Re-entry stabilization and integration planning
- Long-term embodiment and behavioral change frameworks

### Phase 3: Phase 3: The Art of Space Holding

Facilitation is not control. It is steadiness under intensity. This phase trains internal regulation and discernment.

Topics covered:

- Facilitator nervous system regulation skills
- Somatic awareness and grounded presence
- Projection and countertransference recognition
- Discernment during peak and destabilizing states
- Appropriate intervention versus non-intervention skills

### Phase 4: Phase 4: Ethics, Power, and Professional Integrity

Altered states can amplify vulnerability and power dynamics. This phase develops ethical maturity and accountability.

Topics covered:

- Power dynamics, boundaries, and informed consent
- Ethics of touch and financial transparency
- Transference, countertransference, and inflation risk
- Spiritual bypassing and practitioner inflation awareness
- Ongoing self-inquiry and accountability practices

## Safety & Clinical Standards

Safety is foundational to the program. Trainees are taught to screen for cardiovascular and psychiatric contraindications, understand 5-MeO-DMT pharmacology and drug interactions (including SSRI/MAOI considerations), prepare participants and environments, manage in-session somatic release and airway safety, and provide post-session reactivation grounding and long-term integration. Detailed screening criteria and emergency-response protocols are taught in Phase 1 (Foundation and Safety).

## Ethics, Power & Professional Integrity

Phase 4 addresses the heightened vulnerability and power dynamics of altered-state work. Trainees develop ethical maturity, clear boundaries, informed-consent practices, and accountability structures that distinguish professional 5-MeO-DMT facilitation from casual use.

## Frequently Asked Questions

### Is this training right for me?

This program is designed for professionals and serious practitioners who feel genuinely called to responsible 5-MeO-DMT facilitation. Many students are licensed therapists, medical professionals, experienced facilitators, and coaches seeking deeper clinical and ethical grounding. It is not a curiosity course or weekend certification. Admission requires a 60-minute private interview with Kerby.

### What does the interview involve?

A required 60-minute private conversation with Kerby. You'll discuss your background and intentions, explore the curriculum and learning platform, get your questions answered, and determine whether the upcoming cohort is the right mutual fit.

### What is the tuition and when do I pay the deposit?

Tuition is $5,500. The $500 deposit is offered only after you complete the interview and are accepted into the cohort. From the first day of live training, students have a three-week evaluation period. If you withdraw during that window, all tuition paid is refunded minus the $500 deposit. After the three-week period, tuition becomes non-refundable.

### Why is the program 12 months long?

Facilitation competency requires time, repetition, supervision, and personal integration. The first six months focus on live training. The following six months provide mentorship, case consultation, and continued refinement.

### What happens after the live training phase?

After the initial six months of weekly classes, students enter a six-month mentorship and apprenticeship period with case discussions, applied supervision, and continued integration training.

### Can I download the course materials?

Recorded trainings and materials remain accessible through the student portal for the duration of the program and beyond. Materials are not available for bulk download or redistribution.

### When does the next cohort begin?

The next cohort begins March 7, 2027. Schedule your private cohort interview to confirm fit and secure consideration for this cohort. Cohort size is capped so every student receives supervision and mentorship from the faculty.

## Related Resources

- [5-MeO-DMT Facilitator Training Program (HTML)](https://mindscapeinstitute.org/courses/5-meo-dmt-facilitation)
- [Training program markdown](https://mindscapeinstitute.org/training.md)
- [llms.txt index](https://mindscapeinstitute.org/llms.txt)
- [All courses](https://mindscapeinstitute.org/courses)
- [About Mindscape Institute](https://mindscapeinstitute.org/about)

# Research & Evidence Base (Medicines Explained)

> Direct-answer summaries of the clinical evidence for each compound taught at Mindscape, with peer-reviewed citations. Source page: https://mindscapeinstitute.org/research

## 5-MeO-DMT (Bufo Alvarius)

**What it is.** 5-MeO-DMT is a fast-acting tryptamine found naturally in the Sonoran Desert toad and several plants. It produces the shortest, most intense experience of the classical psychedelics — typically under 30 minutes when vaporized. Clinically it is the most researched as an antidepressant; in 2026 a randomized trial reported remission in over half of treatment-resistant depression patients within eight days of a single-day dosing protocol.

**How it works.** Unlike classical psychedelics that act mainly on the serotonin 2A receptor, 5-MeO-DMT binds most strongly to the serotonin 1A receptor. That difference is why its effects feel qualitatively different: rapid onset, brief duration, and a high rate of complete ego dissolution, per peer-reviewed pharmacology reviews.

**Where the evidence stands.** Evidence is early but accelerating. A phase 2b randomized controlled trial published in JAMA Psychiatry in 2026 reported 57.5% remission at day 8 versus 0% on placebo in treatment-resistant depression. Systematic reviews report low adverse-event rates in supportive settings, and 2024 field research documents naturalistic use patterns. The evidence base is not yet at psilocybin or ketamine maturity, which is why structured facilitation and screening matter.

**Key cautions.** The intensity profile is the main risk factor: reviews describe a distinct risk profile tied to dosing, setting, and cardiovascular screening. Trauma-informed preparation and integration correlate with better outcomes. Legal status varies by jurisdiction; facilitation outside approved research contexts carries legal and professional risk.

**Recent developments.** 2025-2026: JAMA Psychiatry published the first large randomized trial of inhaled 5-MeO-DMT (GH001) for treatment-resistant depression; Psychopharmacology published a comprehensive pharmacology and risk review.

Key peer-reviewed studies:
- GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial (Cubala, W.J. et al., 2026, JAMA Psychiatry) — Phase 2b randomized controlled trial: a single-day inhaled mebufotenin (5-MeO-DMT) protocol produced 57.5% remission at day 8 versus 0% on placebo in treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/41879760/
- 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk? (Dourron, H.M. et al., 2025, Psychopharmacology) — Comprehensive review: 5-MeO-DMT's 5-HT1A-dominant pharmacology, ultra-short duration, and intensity profile distinguish it from classical psychedelics, with distinct safety and screening considerations. https://pubmed.ncbi.nlm.nih.gov/38072874/
- Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT): a systematic review (Kwaśny, A. et al., 2024, Frontiers in Psychiatry) — Systematic review of safety data: adverse events are typically mild and transient in screened settings; screening and dose control drive risk. https://pubmed.ncbi.nlm.nih.gov/39364380/
- A narrative synthesis of research with 5-MeO-DMT (Ermakova, A.O. et al., 2022, Journal of Psychopharmacology) — Synthesis of the 5-MeO-DMT literature: intense experience profile, use patterns, and the research gaps that structured facilitation must address. https://pubmed.ncbi.nlm.nih.gov/34666554/
- Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence and Characteristics (Ortiz Bernal, A.M. et al., 2025, Journal of Psychoactive Drugs) — Field study of post-experience reactivations: their prevalence, triggers, and management inform preparation protocols for safe practice. https://pubmed.ncbi.nlm.nih.gov/41129673/

## Ketamine-Assisted Therapy

**What it is.** Ketamine is an approved anesthetic whose rapid antidepressant effect has made it the most clinically established psychedelic-assisted treatment. It is legally prescribable off-label for treatment-resistant depression, and its derivative esketamine carries FDA approval. It is the only one of the four compounds here that clinicians can incorporate into licensed practice today.

**How it works.** Ketamine blocks NMDA receptors, which triggers a glutamate surge and downstream AMPA activation — a mechanism distinct from SSRIs. This drives the rapid but time-limited antidepressant effect, which is why psychotherapy integration around each dosing session is central to durable outcomes.

**Where the evidence stands.** The evidence base is the deepest in the field: multiple randomized trials and meta-analyses report 60-70% response rates in treatment-resistant depression, a 2024 Nature Medicine trial showed significant PTSD reduction with ketamine-assisted psychotherapy at six months, and a 2025 systematic review compared IV ketamine against esketamine head-to-head.

**Key cautions.** Dissociation and blood-pressure elevation during dosing require medical screening and monitoring. Effects fade without repetition or psychotherapy, so treatment design matters more than the drug alone. Abuse liability calls for careful patient selection.

**Recent developments.** 2025: a systematic review and meta-analysis directly compared IV ketamine with esketamine for depression, sharpening route-of-administration decisions.

Key peer-reviewed studies:
- Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine: a randomized, placebo-controlled, phase 2 dose-finding trial (MacConnel, H.A. et al., 2025, Journal of Psychopharmacology) — Randomized phase 2 trial: IV ketamine produced rapid, sustained reductions in treatment-resistant PTSD symptoms versus placebo. https://pubmed.ncbi.nlm.nih.gov/39400075/
- Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis (Elmosalamy, A. et al., 2025, Therapeutic Advances in Psychopharmacology) — Head-to-head meta-analysis comparing IV ketamine with esketamine across efficacy and safety, informing route-of-administration choices in clinical practice. https://pubmed.ncbi.nlm.nih.gov/41244961/
- Ketamine combined with psychotherapy for treatment-resistant depression: Real-world evidence (Cohen, R. et al., 2026, General Hospital Psychiatry) — Real-world data on ketamine paired with psychotherapy in treatment-resistant depression — the combination model this training teaches. https://pubmed.ncbi.nlm.nih.gov/41690063/
- Distinct therapeutic profiles of ketamine in treatment-resistant depression: a systematic review (Liu, K.I. et al., 2026, International Journal of Neuropsychopharmacology) — Systematic review separating ketamine's rapid antidepressant profile from its longer-term therapeutic pattern in treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/42059646/
- Dose-dependent adverse events of esketamine in treatment-resistant depression (Qu, Y. et al., 2026, Frontiers in Pharmacology) — Adverse-event analysis across esketamine doses: medical monitoring thresholds for route and dose selection in clinical practice. https://pubmed.ncbi.nlm.nih.gov/42292802/

## Psilocybin-Assisted Therapy

**What it is.** Psilocybin is the active compound in so-called magic mushrooms. After ingestion it converts to psilocin and produces a 4-6 hour experience. It is the most-studied psychedelic in psychiatry, with late-stage trials in treatment-resistant depression underway and no approval yet outside research settings.

**How it works.** Psilocin, the active metabolite, stimulates serotonin 2A receptors, which temporarily loosens the brain's default mode network — the network tied to rigid self-focus in depression. The subjective experience appears to open a window during which psychotherapy can rework entrenched patterns.

**Where the evidence stands.** Randomized trials show rapid, sustained antidepressant effects in major depression, positive results for alcohol use disorder and cancer-related existential distress, and — in 2025 — a 52-week follow-up study in the Journal of Clinical Psychiatry reported that a single 25 mg dose held longer-term antidepressant effects in treatment-resistant depression. A first phase 3 program reported positive topline results in 2025.

**Key cautions.** Psychological screening is essential: personal or family psychosis and bipolar history are standard exclusions. Sessions require hours of supervised support, and adverse events cluster around unsupervised or recreational settings rather than supervised ones.

**Recent developments.** 2025: 52-week follow-up of the 25 mg single-dose protocol published in the Journal of Clinical Psychiatry; the first phase 3 program in treatment-resistant depression hit its primary endpoint.

Key peer-reviewed studies:
- Long-term Follow-up Study of a Single Dose of Synthetic Psilocybin in Treatment-Resistant Depression (COMP004) (Goodwin, G.M. et al., 2025, Journal of Clinical Psychiatry) — 52-week observational follow-up: a single 25 mg COMP360 psilocybin dose showed longer-term antidepressant effects than lower doses, with response durability across a year. https://www.psychiatrist.com/jcp/long-term-follow-up-study-single-dose-psilocybin-treatment-resistant-episode-major-depressive-disorder/
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial (Raison, C.L. et al., 2023, JAMA) — Landmark randomized trial in JAMA: a single 25 mg psilocybin session with psychotherapy produced rapid, sustained antidepressant effects. https://pubmed.ncbi.nlm.nih.gov/37651119/
- Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial (Rosenblat, J.D. et al., 2024, Med) — Independent randomized trial replicating single-dose psilocybin efficacy in treatment-resistant depression — evidence beyond the originating group. https://pubmed.ncbi.nlm.nih.gov/38359838/
- Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer (Agin-Liebes, G.I. et al., 2020, Journal of Psychopharmacology) — Follow-up data: anxiety and depression reductions after psilocybin-assisted psychotherapy persisted at long-term follow-up in patients with life-threatening cancer. https://pubmed.ncbi.nlm.nih.gov/31916890/
- Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin (Lebedev, A.V. et al., 2015, Human Brain Mapping) — Neuroimaging study linking psilocybin-induced ego dissolution to disorganized activity in association networks — the mechanistic basis of the experience. https://pubmed.ncbi.nlm.nih.gov/26010878/

## MDMA-Assisted Therapy

**What it is.** MDMA is an entactogen: it increases serotonin, oxytocin, and norepinephrine release, which reduces fear and increases trust during therapy sessions. It is not a classic psychedelic; its clinical value lies in making trauma processing tolerable. It remains an investigational compound — the FDA declined approval in 2024 and requested an additional trial.

**How it works.** By flooding the brain with serotonin and oxytocin while dampening the amygdala's fear response, MDMA creates a window of emotional openness. Within a structured therapy protocol, patients revisit traumatic memories without the usual flooding, which lets reconsolidation-based processing work.

**Where the evidence stands.** Two phase 3 trials (MAPP1, 2021; MAPP2, 2023, in Nature Medicine) showed significant PTSD symptom reduction with MDMA-assisted therapy, with benefits sustained in long-term follow-up. The FDA's 2024 complete response letter cited safety and data-quality concerns and requested an additional trial; approval remains pending, not rejected outright.

**Key cautions.** Cardiovascular screening is mandatory — MDMA raises heart rate and blood pressure. Because the compound increases trust and reduces threat perception, protocol integrity and screened therapist pairs matter; this is the area the FDA scrutinized.

**Recent developments.** 2024-2025: the FDA issued a complete response letter requesting an additional trial; the field is regrouping around protocol and data-quality improvements.

Key peer-reviewed studies:
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (Mitchell, J.M. et al., 2023, Nature Medicine) — Pivotal phase 3 trial (MAPP2): MDMA-assisted therapy significantly reduced PTSD symptoms, with 67% no longer meeting PTSD criteria at endpoint. https://pubmed.ncbi.nlm.nih.gov/37709999/
- Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: a systematic review and meta-analysis (Fares-Otero, N.E. et al., 2026, European Neuropsychopharmacology) — Meta-analysis pooling the MDMA-assisted therapy trials for PTSD: effect sizes, responder rates, and the safety picture across phase 2-3 studies. https://pubmed.ncbi.nlm.nih.gov/41825162/
- Psychedelics: A review of their effects on recalled aversive memories and fear extinction (Werle, I. et al., 2024, Neuroscience & Biobehavioral Reviews) — Review of how psychedelics including MDMA affect aversive memory reconsolidation and fear extinction — the mechanism behind MDMA-assisted trauma therapy. https://pubmed.ncbi.nlm.nih.gov/39305969/
- Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) (Ramaekers, J.G. et al., 2026, Molecular Psychiatry) — Controlled profiling of clinical MDMA doses: subjective and cognitive effects that define the therapeutic window. https://pubmed.ncbi.nlm.nih.gov/41951837/